Palsson 2002: The North Carolina Protocol, What 24 Patients in Chapel Hill Showed (Honest Breakdown)

Why this paper matters (the US standardization story)

Through the 1980s and most of the 1990s, the published evidence base for gut-directed hypnotherapy in IBS was almost entirely a UK story. The foundational Whorwell, Prior, and Faragher trial in The Lancet 1984 came out of Manchester. The Manchester Protocol that emerged from that trial was refined at Withington Hospital across the next two decades and is documented in the Gonsalkorale 2003 Gut audit of more than 250 patients treated through that service. For a US gastroenterologist wanting to refer a patient for gut-directed hypnotherapy in the late 1990s, the practical problem was that the Manchester Protocol was developed and primarily practiced inside a UK NHS specialty clinic with its own training pipeline, and there was no equivalent standardized US protocol with a published format that a US-trained clinical psychologist or hypnotherapist could pick up and implement.

Olafur Palsson, a clinical psychologist at the University of North Carolina at Chapel Hill working with William Whitehead's IBS research group, developed a standardized 7-session protocol designed to be implementable by trained US clinicians outside a specialty NHS context. The 2002 Digestive Diseases and Sciences paper is the first peer-reviewed publication of that protocol applied prospectively in a defined patient cohort with structured outcome measurement.

This is why the paper matters even though it is a single-arm trial. The structural contribution to the field was not 'we proved hypnotherapy works' (that proof was already starting to accumulate from the Manchester arm of the literature). The structural contribution was 'here is a fully specified protocol with a written session-by-session format, validated on a 24-patient severe IBS cohort, with documented response rates and prospective follow-up.' Other clinicians could then read the paper, train on the protocol, and use it. Most US gut-directed hypnotherapy practice today (and a substantial fraction of Canadian practice) traces back to this protocol either directly through clinicians trained by Palsson or indirectly through training programs that incorporated the North Carolina protocol alongside or instead of the Manchester Protocol.

Palsson has continued to publish from UNC Chapel Hill across the two decades since this paper, contributing to much of the US-based published evidence on gut-brain axis interventions for functional GI disorders. The combination of running the protocol-development paper and then running much of the subsequent US research literature on related topics gives the North Carolina protocol a unique institutional footprint in the field.

The honest framing: Palsson 2002 is best understood as a protocol-standardization paper that opened the door for US clinical adoption, with usable internal evidence (80 percent response rate within the treated cohort, sustained at 10 months) that justified the protocol enough to publish and replicate. It is not the trial that establishes the comparative efficacy of gut-directed hypnotherapy as a class. That work was done by the controlled trials that came before and after.

What the North Carolina protocol actually IS (and how it differs from Manchester)

The Palsson protocol as published in the 2002 paper is a 7-session, individually delivered hypnosis treatment, with sessions roughly weekly. The protocol is fully scripted in the sense that each session has a defined induction, a defined deepening sequence, defined therapeutic suggestions targeting specific aspects of gut function and symptom interpretation, and a defined emergence. Patients are also asked to listen to a home-practice audio recording daily between sessions to reinforce the in-session work.

The core therapeutic content of the protocol can be grouped into a small number of themes. The early sessions establish the hypnotic relationship and teach the patient to enter a focused, relaxed state on demand. The middle sessions introduce specific gut-targeted imagery (slow, smooth, comfortable river or stream imagery for healthy motility; warmth and comfort imagery for the abdomen; imagery of a protective layer between the gut and external stressors). The later sessions consolidate the gains, address residual symptom-specific concerns, and transition the patient into self-management using the home audio.

The differences from the Manchester Protocol are real but smaller than they sometimes get described.

Session count and arc. The Manchester Protocol as documented in Whorwell's original trial and subsequent Gonsalkorale audit is typically 7 to 12 sessions, with the audit data suggesting 12 sessions as the more common modern implementation. The North Carolina protocol is fixed at 7 sessions. Shorter overall arc but in the same range.

Imagery vocabulary. Both protocols use imagery to address visceral hypersensitivity, motility, and the patient's interpretive relationship with symptoms. Manchester famously uses river-flow imagery for motility and protective-shield or warm-glove imagery for the abdomen. North Carolina uses overlapping but not identical imagery, with somewhat more emphasis on imagery the patient develops in dialogue with the clinician rather than imagery handed to the patient as a script.

Cultural register. Manchester evolved inside a UK NHS gastroenterology specialty clinic over many years and reflects that practice culture (longer arc, more clinician-driven imagery, embedded in a specialty referral pathway). North Carolina was designed from the outset to be implementable by US-trained clinical psychologists and hypnotherapists working in a wider variety of practice contexts (shorter arc, more standardized script, more emphasis on the patient being able to continue the work via the home audio after sessions end).

Standardization tightness. This is probably the largest practical difference. The Manchester Protocol has more clinician judgment built in across the arc; the same trained clinician can deliver it differently to different patients depending on what the case presents. The North Carolina protocol is more tightly scripted by design, which makes it more reproducible across different clinicians but offers less per-patient flexibility.

What the protocols share is the core therapeutic theory: gut-directed hypnosis works by changing central pain processing, central symptom interpretation, and the autonomic context the gut operates in, using a hypnotic state to make therapeutic suggestions more available to the patient's emotional and somatic processing. Neither protocol claims to fix peripheral gut pathology directly. Both produce comparable response rates in their respective evidence bases.

Practical implication for a patient or referrer: a properly trained clinician using either protocol is using the same evidence-backed family of interventions. The choice between Manchester and North Carolina in current practice is more often driven by where the practitioner trained (UK pipeline vs US pipeline) than by patient-side considerations. Most experienced gut-directed hypnotherapy clinicians know both protocols and adapt elements from each. For the protocol's UK ancestor, see the Whorwell 1984 RCT deep dive.

What the symptom + psychology + autonomic data showed

The Palsson 2002 paper is unusual among the early gut-directed hypnotherapy trials in that it explicitly investigated mechanism alongside symptom outcome. The trial measured three categories of outcome: bowel symptoms (the clinical endpoint that matters most to patients), psychological symptoms (anxiety, depression, somatization), and physiological mechanism markers (rectal sensitivity via balloon distension, autonomic measures including heart rate variability and electrodermal activity).

Bowel symptoms. Roughly 80 percent of the 24 patients showed clinically meaningful improvement on the trial's bowel symptom scoring at end of treatment. The trial used a composite bowel symptom score that combined frequency and severity of abdominal pain, abdominal distension or bloating, and abnormal bowel habit. The 80 percent figure refers to patients meeting the response definition Palsson specified in advance. The magnitude of within-patient symptom change was substantial across the responder group, not borderline.

Psychological symptoms. Scores on anxiety, depression, and somatization scales (administered using validated psychometric instruments standard in clinical psychology research) decreased significantly from pre-treatment to post-treatment. The Palsson group treated this as evidence that the protocol was producing improvement that generalized beyond the specific gut symptoms it was targeting, consistent with a central rather than purely peripheral mechanism of action.

It is worth being careful here. Improvement in anxiety and depression in a patient whose IBS has just improved substantially is not surprising. Being in pain less often is itself an anxiolytic and antidepressant intervention. The psychological improvement is real but does not by itself prove that the protocol is treating anxiety or depression as primary outcomes. It is more consistent with downstream improvement following symptom relief than with the protocol being a direct mental health treatment.

Mechanism markers (the interesting null findings). This is where Palsson 2002 contributes a piece of evidence that few other trials in this field provide. The mechanism arm measured rectal sensitivity to balloon distension (a standardized protocol used in the IBS visceral hypersensitivity literature) before and after treatment. It also measured autonomic markers (heart rate variability, electrodermal activity). The visceral sensitivity threshold did not change significantly with treatment. The autonomic markers also did not change significantly.

Palsson interpreted these null mechanism findings as supportive of a central mechanism rather than a peripheral one. If the protocol produced clinically meaningful bowel symptom improvement without changing visceral sensitivity threshold, the implication is that the protocol changed how the patient interprets or processes visceral signals in the central nervous system, not what visceral signals the gut sends in the first place. This is consistent with the theoretical model that has dominated gut-brain axis work in the two decades since: the gut sends roughly the same signal volume, the brain processes and reacts to that signal differently after hypnotherapy, and the patient experiences reduced symptom burden.

The honest caveat on the mechanism work: small sample (24 patients), single-site, single-protocol, and the absence of measurable change in mechanism markers in a small uncontrolled trial is itself weak evidence. A larger, properly powered mechanism study would be required to make a stronger claim. The mechanism interpretation in Palsson 2002 is consistent with subsequent neuroimaging and physiology work in the field but is not by itself definitive.

The 10-month follow-up, durability without a control group

End-of-treatment response in an IBS trial is the less informative number. The number that actually matters for treatment decisions is durability. A protocol that works for 6 weeks and then unwinds is a different proposition from a protocol whose benefit persists for many months or years after sessions end.

Palsson and colleagues followed patients prospectively to a 10-month post-treatment timepoint. At follow-up, the substantial majority of patients who had responded at end of treatment had maintained their symptom improvement. The bowel symptom gains were largely durable across the 10-month window.

This is an important data point and it is also where the lack of a control group is most consequential.

In a randomized controlled trial with an active control arm, the relevant durability question is 'does the treated group maintain its advantage over the control group across the follow-up window.' If both arms drift toward the same point, the treatment effect has unwound. If the treated group stays ahead, the treatment effect is durable. That is the design Moser 2013 used in the Vienna trial at 15 months, where the hypnotherapy arm maintained a clear advantage over the active control at the longest prospective follow-up in the field (see the Moser 2013 Vienna RCT breakdown for the granular numbers).

In a single-arm pre-post trial like Palsson 2002, the only available comparison is within-patient: where the patient was before treatment vs where the patient is at follow-up. That comparison cannot distinguish the durable effect of the treatment from the natural course of IBS over the same window. Severe IBS does fluctuate. Some patients in any 10-month window will improve regardless of intervention. Without a parallel control arm experiencing the same window without the intervention, the durability finding is suggestive but not definitive.

The defensible read of the Palsson 2002 durability data is: in this 24-patient severe IBS cohort, the improvement that occurred during the 7-session intervention period was largely retained 10 months later. That is consistent with the broader literature on gut-directed hypnotherapy durability (Whorwell 1987 BMJ follow-up to 18 months in the original Manchester cohort; Gonsalkorale 2003 Gut audit showing 81 percent of responders maintaining benefit at median 5-year follow-up in 250+ patients; Moser 2013 Am J Gastroenterol showing 54 percent of hypnotherapy patients meeting responder criterion at 15 months vs 25 percent of active control). Read alongside the controlled durability evidence, the Palsson 2002 10-month finding adds to the consistency of the picture even though the design does not let it stand alone.

Honest limitations: pre-post design, n=24, single-site

Any responsible read of Palsson 2002 has to hold the limitations alongside the headline findings. The limitations here are more consequential than they are for the parallel-controlled RCTs in this literature, because the design is structurally weaker.

Pre-post design with no control group. This is the single most important limitation and the one most often glossed over in casual citations of the 80 percent response figure. A single-arm trial where every patient receives the active intervention cannot rule out the specific alternative explanations that a controlled trial is designed to rule out. Specifically: regression to the mean (patients selected when their symptoms are at their worst tend to improve toward their personal average regardless of intervention), expectation effects (patients who are paying for and committing to an intervention they believe will help are predisposed to report improvement), attention effects (the act of having a clinician's structured attention for 7 sessions over multiple months is itself therapeutic regardless of the specific protocol content), and natural fluctuation (severe IBS waxes and wanes over months). None of these alternative explanations can be cleanly separated from the specific effect of the North Carolina protocol in a pre-post design.

Sample size of 24 is small. Even setting aside the design issue, 24 patients is a small cohort. Confidence intervals on the response rate are wide. A response rate of 80 percent in 24 patients is consistent with a true population response rate substantially lower (or higher) once enough patients are studied to narrow the interval. The 80 percent figure is not the population response rate. It is the point estimate from a small uncontrolled cohort, and a research-aware reader is right to discount it accordingly.

Single-site at UNC Chapel Hill. All patients were recruited and treated through one academic GI service. The treating clinician was Palsson himself, the developer of the protocol. Both factors limit generalizability. The protocol implemented at maximum fidelity by its inventor in a tertiary academic context may not produce the same response rate when delivered by other clinicians in community settings. The subsequent two decades of clinical replication of the North Carolina protocol across other US practices suggests the protocol does travel, but Palsson 2002 alone does not establish that.

Severe IBS population. The trial enrolled severe IBS patients (the original paper specifies severity criteria, with patients having symptom burden in the substantial-to-disabling range). This is appropriate for an early protocol-validation study (a refractory population gives the cleanest signal) but means the response rate cannot be assumed to generalize directly to milder IBS. The Whorwell 1984 trial made the same design choice and the broader literature has since confirmed gut-directed hypnotherapy works across IBS severity, but Palsson 2002 by itself is a severe-population datapoint.

Pre-Rome III era criteria. The trial used IBS diagnostic criteria current at the time of conduct (Rome I or early Rome II era). Subsequent revisions to the Rome criteria have tightened symptom definitions. Patients who would meet the trial's inclusion criteria may not all meet current Rome IV criteria, and vice versa. This is a minor issue that applies to all pre-2006 IBS trials.

Mechanism arm is exploratory. The visceral sensitivity and autonomic measures are an interesting addition but the mechanism arm is underpowered to make strong mechanism claims. The null findings on visceral sensitivity and autonomic markers are consistent with a central mechanism but do not establish it.

What the limitations do NOT mean. They do not mean Palsson 2002 is a bad paper or that the North Carolina protocol does not work. They mean Palsson 2002 should be read as a protocol-standardization paper with usable internal validation evidence, contextualized inside the broader controlled-trial literature on gut-directed hypnotherapy. The protocol's strongest evidence base comes from reading this paper alongside Whorwell 1984, Moser 2013, Peters 2016, and Lindfors 2012, not from reading it alone.

Manchester vs North Carolina: do practitioners use one or both?

A reasonable question from a research-aware reader trying to choose a practitioner is which protocol the clinician uses, and whether that choice matters.

The honest answer in current practice is that most experienced gut-directed hypnotherapy clinicians are trained on at least one of the two protocols, many are trained on both, and the practical difference at the patient level is smaller than the literature footprint of each suggests.

How clinicians end up trained on which protocol. This is largely a function of where they trained. Clinicians trained through UK pipelines (Manchester-affiliated programs, UK postgraduate clinical psychology training that includes a gut-directed hypnotherapy module, training routes connected to the Whorwell or Gonsalkorale lineage) are typically trained on the Manchester Protocol first. Clinicians trained through US pipelines (UNC-affiliated programs, IFFGD-connected training, US clinical psychology programs that include functional GI specialization, the Palsson-developed training resources) are typically trained on the North Carolina protocol first. Most experienced practitioners pick up the second protocol later either through continuing education or through reading and protocol-adaptation as they encounter cases that benefit from the alternative framework.

What the choice means for outcomes. Both protocols have published evidence of efficacy. Neither has a head-to-head trial against the other showing superiority. The expected outcome difference for a given patient is small or zero across the two protocols. The much larger source of outcome variance is practitioner training and experience: a well-trained clinician using either protocol consistently produces better outcomes than a poorly trained clinician using either protocol inconsistently.

What to ask a practitioner. The high-value questions for a prospective patient evaluating a gut-directed hypnotherapy clinician are not 'which protocol do you use' but rather: how were you trained in gut-directed hypnotherapy specifically (as opposed to general hypnotherapy), how many gut-directed cases have you taken through a full protocol arc, do you follow a named protocol (Manchester, North Carolina, or a documented adaptation) rather than improvising session by session, and do you assign home practice audio between sessions. A 'yes' to a named protocol and a meaningful answer on case count are stronger quality signals than the specific protocol name.

At Calgary Gut Hypnotherapy. I trained primarily through resources rooted in the Palsson North Carolina protocol with extensive incorporation of Manchester Protocol elements (the imagery vocabulary, the longer-arc structure used selectively in cases that benefit from it). The practical implementation is a 6 to 8 session arc with daily home audio practice, drawing on the documented evidence base from both protocols. The book-keeping point: any practitioner you book in the gut-directed hypnotherapy space should be able to name the protocol family they work in and walk you through the evidence chain. The credentialing layer is separate from the protocol layer: ARCH (Association of Registered Clinical Hypnotherapists of Canada) is Canada's most stringent voluntary professional body for clinical hypnotherapy. A practitioner who is ARCH-credentialed and works from a named protocol is the high end of the Canadian distribution.

Cost in Canada. At Calgary Gut Hypnotherapy, sessions are $220 to $350 depending on complexity, with a 3-session minimum commitment ($660 to $1,050) and a full protocol typically running 6 to 8 sessions ($1,320 to $2,800). Most Canadian generalist hypnotherapists charge $150 to $300 per session with high variance because hypnotherapy is not a regulated profession.

Insurance honest section. Hypnotherapy isn't directly covered by Canadian provincial health plans or most extended health benefit plans. Hypnotherapy isn't a regulated profession in Alberta. Some clients get reimbursement through their employer's Wellness Spending Account (WSA) under categories like 'stress management' or 'mental wellness'. WSAs are different from Health Spending Accounts (HSAs), which follow strict CRA medical-expense rules that exclude practitioners who aren't on a provincial regulated list. Always check with your specific plan whether RCH services qualify.